StoneX Group Inc. Common Stock vs 22nd Century Group Inc — how do they compare? StoneX Group Inc. Common Stock trades at $59.76 (market cap $7.27B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: StoneX Group Inc. Common Stock is far larger — about 15274.7× 22nd Century Group Inc's market cap, and StoneX Group Inc. Common Stock is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold StoneX Group Inc. Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| SNEX | XXII | |
|---|---|---|
Market Cap | $7.27B | $475.95K |
Volume | 1,624,795 | 78,911 |
Sector | Financials | Consumer Staples |
52-Week High | $92.67 | $483.00 |
52-Week Low | $37.20 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $28.28B | -$3.83M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
StoneX Group Inc. is a financial services firm providing trading, clearing, execution, and cross-border payment services to institutional, commercial, and self-directed retail clients across global markets.
Read more on SNEX →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →